EUVIMEDEUVIMED entdecken
Crossref

Non-HDL Cholesterol May Be Preferred over Apolipoprotein B-100 for Risk Assessment when Evaluated by Receiver Operator Characteristic Curve Analysis

Stanley S Levinson

The Journal of Applied Laboratory Medicine · 2025

DOI: 10.1093/jalm/jfae125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2025. Verfasst von Stanley S Levinson. Beteiligte Einrichtung: Department of Medicine, Section of Endocrinology, Metabolism and Diabetes, University of Louisville, Louisville, KY, United States. Hauptthemen laut MEDLINE: Apolipoprotein B-100, Cholesterol. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Most studies found that apolipoprotein B (apo B)-100 is a superior marker for coronary risk to non-high-density lipoprotein (HDL) cholesterol (C). Usually, studies use multivariant analysis with single-point odds/risk ratios. In multivariant analysis, when variables are highly correlated they are difficult to interpret. Effects cannot be well discriminated.

Methods

Brief review and examination of diagnostic sensitivity and specificity by receiver operator characteristic (ROC) curves at decision levels so that discrimination can be well compared. Since apo B has additional expense, clinical value should be compared in an appropriate format. Apo B and cholesterols were measured in 382 angiographically defined patients.

Results

Non-HDLC and apo B were stronger markers than low-density lipoprotein (LDL)C, when examined by logistic regression, but as a result of strong collinearity, non-HDLC appeared weaker than LDLC in the presence of apo B, based on P values. This was true when analyzed with and without nonlipid risk factors. On ROC analysis, apo B and non-HDLC showed stronger C statistics than LDLC and total C. When analyzed alone apo B showed about 6.1% greater sensitivity than non-HDLC. After adjustment for nonlipid risk factors, the C statistics for apo B and non-HDLC were 0.74 and 0.73, and there was little difference in diagnostic specificity.

Conclusions

Risk is calculated from an algorithm that includes nonlipid risk factors similar to those examined here along with cholesterols. When assessed by the 10-year screening algorithm, these data support the view that non-HDLC would be less expensive than apo B with similar clinical efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein B-100CholesterolHumansROC CurveRisk AssessmentBiomarkersCholesterol, HDLCholesterol, LDLMaleMiddle AgedFemaleAgedRisk FactorsSensitivity and Specificity

Substanzen

Apolipoprotein B-100BiomarkersCholesterol, HDLCholesterolCholesterol, LDL

Autor:innen und Institutionen

  • Department of Medicine, Section of Endocrinology, Metabolism and Diabetes, University of Louisville, Louisville, KY, United States.

Zitieren

APA

Levinson, S. S. (2025). Non-HDL Cholesterol May Be Preferred over Apolipoprotein B-100 for Risk Assessment when Evaluated by Receiver Operator Characteristic Curve Analysis. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae125

Vancouver

Levinson SS. Non-HDL Cholesterol May Be Preferred over Apolipoprotein B-100 for Risk Assessment when Evaluated by Receiver Operator Characteristic Curve Analysis. The Journal of Applied Laboratory Medicine. 2025. doi:10.1093/jalm/jfae125

BibTeX
@article{Levinson2025,
  author = {Levinson, Stanley S},
  title = {Non-HDL Cholesterol May Be Preferred over Apolipoprotein B-100 for Risk Assessment when Evaluated by Receiver Operator Characteristic Curve Analysis},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2025},
  doi = {10.1093/jalm/jfae125}
}
Kostenlos starten →